Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6729354 | 0.91 | PTGS2 (0.51) | PTGS2PTGS1GRM2 | |
| SCHEMBL6722069 | 0.90 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL7537652 | 0.84 | PTGS2 (0.54) | PTGS2PTGS1 | |
| SCHEMBL7111850 | 0.84 | PTGS2 (0.57) | PTGS2PTGS1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL6725700 | 0.83 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6740287 | 0.83 | PTGS2 (0.49) | PTGS2PTGS1 | |
| SCHEMBL7538872 | 0.82 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL7545945 | 0.82 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL7537415 | 0.82 | PTGS2 (0.41) | PTGS2PTGS1GRM2 | |
| SCHEMBL6732439 | 0.81 | PTGS2 (0.43) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | PTGS2 5/4885PTGS1 4/4885GRM2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.